Cookies on the
LGC website
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on the LGC website. However, if you would like to, you can change your cookie settings at anytime.
Question markFind out more

Within the next 35 years, antimicrobial resistance is estimated to account for a staggering 45% of global deaths, potentially as many as 1 every 3 seconds.

The European-funded project AntiMicroResist (AMR) aims to apply innovative metrological concepts to underpin diagnostic analysis and support standardisation of antimicrobial resistance testing through the development of reference methods and materials. This will help inform treatment choice and will deliver a step change in how microbial resistance is evaluated, treated and managed in the future.

AntiMircoResist will work with hospitals and key stakeholder charities to develop the metrology needed to manage antimicrobial resistance.

The background

In 2014 a World Health Organisation (WHO) report revealed that antimicrobial resistance (AMR) is becoming an increasingly serious threat to global public health, putting at risk our ability to treat common infections and making the threat of a post-antibiotic era a very real possibility for the 21st century. A coordinated global effort is required to effectively combat this threat.

The recently released (2016) final report of the UK government-commissioned Review on Antimicrobial Resistance[1] outlines recommendations to combat the high economic and health costs if AMR is allowed to increase. This has been predicted to be associated with a cumulative loss of global economic output of US$100 trillion to 2050, which compounded with a substantial increase in infant and child mortality may also put an end to key advances in medical areas such as surgery and cancer treatment.

Current European activities lack rudimentary metrological considerations more commonly applied to other areas of clinical chemistry. AntiMicroResist aims to support the standardisation of comparable and traceable measurements the fight to reduce AMR.

The project

For further detail on this project download the publishable summary.

The consortium

The consortium delivering AntiMicroResist brings together 11 partners from 5 countries across the EC.

It consists of:

  • six National Measurements Institutes/Designated Institutes (LGC, LNE, NIB, NPL, PTB, TUBITAK)
  • one university (UCL)
  • three hospitals (GOSH, UCG, UWH)
  • one stakeholder charity (BSAC).


[1] Tackling drug-resistant infections globally: Final report and recommendations (2016)

Find out more

For a more detailed project overview, download the publishable summary


Upcoming events

Early 2019: AMR& NGS workshop to be held in London (contact us or check back for updates)

Recent publications

Binary encoding of random peptide sequences for selective and differential antimicrobial mechanisms (Hayouka et al (2017) Angew Chem Int Ed 56:8099)

Antimicrobial peptide capsids of de novo design (De Santis et al (2017) Nat Commun 8:2263, open access)

Contact us

To find out more about this project email us.

Consortium members

Log-in to the AMR Sharepoint site.